Literature DB >> 23891181

Synthesis and antifungal activities of miltefosine analogs.

Ranga Rao Ravu1, Ying-Lien Chen, Melissa R Jacob, Xuewen Pan, Ameeta K Agarwal, Shabana I Khan, Joseph Heitman, Alice M Clark, Xing-Cong Li.   

Abstract

Miltefosine is an alkylphosphocholine that shows broad-spectrum in vitro antifungal activities and limited in vivo efficacy in mouse models of cryptococcosis. To further explore the potential of this class of compounds for the treatment of systemic mycoses, nine analogs (3a-3i) were synthesized by modifying the choline structural moiety and the alkyl chain length of miltefosine. In vitro testing of these compounds against the opportunistic fungal pathogens Candida albicans, Candida glabrata, Candida krusei, Aspergillus fumigatus, and Cryptococcus neoformans revealed that N-benzyl-N,N-dimethyl-2-{[(hexadecyloxy)hydroxyphosphinyl]oxy}ethanaminium inner salt (3a), N,N-dimethyl-N-(4-nitrobenzyl)-2-{[(hexadecyloxy)hydroxyphosphinyl]oxy}ethanaminium inner salt (3d), and N-(4-methoxybenzyl)-N,N-dimethyl-2-{[(hexadecyloxy)hydroxyphosphinyl]oxy}ethanaminium inner salt (3e) exhibited minimum inhibitory concentrations (MIC) of 2.5-5.0 μg/mL against all tested pathogens, when compared to miltefosine with MICs of 2.5-3.3 μg/mL. Compound 3a showed low in vitro cytotoxicity against three mammalian cell lines similar to miltefosine. In vivo testing of 3a and miltefosine against C. albicans in a mouse model of systemic infection did not demonstrate efficacy. The results of this study indicate that further investigation will be required to determine the potential usefulness of the alkylphosphocholines in the treatment of invasive fungal infections.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alkylphosphocholine; Antifungal; Candidiasis; Cryptococcosis; Miltefosine

Mesh:

Substances:

Year:  2013        PMID: 23891181      PMCID: PMC3760157          DOI: 10.1016/j.bmcl.2013.06.096

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  26 in total

1.  Synthesis and biological activity of dialkylphosphocholines.

Authors:  Milos Lukác; Martin Mrva; Eva Fischer-Fodor; Ivan Lacko; Marián Bukovský; Natalia Miklásová; Frantisek Ondriska; Ferdinand Devínsky
Journal:  Bioorg Med Chem Lett       Date:  2009-09-24       Impact factor: 2.823

2.  In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci.

Authors:  Daniel Llull; Luis Rivas; Ernesto García
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

3.  Potent in vitro antifungal activities of naturally occurring acetylenic acids.

Authors:  Xing-Cong Li; Melissa R Jacob; Shabana I Khan; M Khalid Ashfaq; K Suresh Babu; Ameeta K Agarwal; Hala N Elsohly; Susan P Manly; Alice M Clark
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

Review 4.  Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy.

Authors:  Stefan R Vink; Wim J van Blitterswijk; Jan H M Schellens; Marcel Verheij
Journal:  Cancer Treat Rev       Date:  2007-02-06       Impact factor: 12.111

5.  Dialkylamino and nitrogen heterocyclic analogues of hexadecylphosphocholine and cetyltrimetylammonium bromide: effect of phosphate group and environment of the ammonium cation on their biological activity.

Authors:  Milos Lukác; Ján Mojzis; Gabriela Mojzisová; Martin Mrva; Frantisek Ondriska; Jindra Valentová; Ivan Lacko; Marián Bukovský; Ferdinand Devínsky; Janka Karlovská
Journal:  Eur J Med Chem       Date:  2009-09-02       Impact factor: 6.514

6.  Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

Authors:  Thomas P C Dorlo; Pieter P A M van Thiel; Alwin D R Huitema; Ron J Keizer; Henry J C de Vries; Jos H Beijnen; Peter J de Vries
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

7.  Synthesis, antifungal and antimicrobial activity of alkylphospholipids.

Authors:  Daniel Obando; Fred Widmer; Lesley C Wright; Tania C Sorrell; Katrina A Jolliffe
Journal:  Bioorg Med Chem       Date:  2007-05-17       Impact factor: 3.641

8.  Antileishmanial structure-activity relationships of synthetic phospholipids: in vitro and in vivo activities of selected derivatives.

Authors:  Karin Seifert; Andreas Lemke; Simon L Croft; Oliver Kayser
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

9.  Hexadecylphosphocholine interferes with the intracellular transport of cholesterol in HepG2 cells.

Authors:  María P Carrasco; José M Jiménez-López; Josefa L Segovia; Carmen Marco
Journal:  FEBS J       Date:  2008-02-27       Impact factor: 5.542

10.  Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy.

Authors:  Pauline Chugh; Birgit Bradel-Tretheway; Carlos M R Monteiro-Filho; Vicente Planelles; Sanjay B Maggirwar; Stephen Dewhurst; Baek Kim
Journal:  Retrovirology       Date:  2008-01-31       Impact factor: 4.602

View more
  6 in total

1.  Miltefosine Has a Postantifungal Effect and Induces Apoptosis in Cryptococcus Yeasts.

Authors:  Cristina de Castro Spadari; Taissa Vila; Sonia Rozental; Kelly Ishida
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

2.  A P4-ATPase subunit of the Cdc50 family plays a role in iron acquisition and virulence in Cryptococcus neoformans.

Authors:  Guanggan Hu; Mélissa Caza; Erik Bakkeren; Matthias Kretschmer; Gaurav Bairwa; Ethan Reiner; James Kronstad
Journal:  Cell Microbiol       Date:  2017-01-23       Impact factor: 3.715

3.  In vitro combination of voriconazole and miltefosine against clinically relevant molds.

Authors:  S Imbert; M Palous; I Meyer; E Dannaoui; D Mazier; A Datry; A Fekkar
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

4.  In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis.

Authors:  Taissa Vieira Machado Vila; Ashok K Chaturvedi; Sonia Rozental; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

Review 5.  New Approaches for Cryptococcosis Treatment.

Authors:  Cristina de Castro Spadari; Fernanda Wirth; Luciana Biagini Lopes; Kelly Ishida
Journal:  Microorganisms       Date:  2020-04-23

6.  Alginate nanoparticles as non-toxic delivery system for miltefosine in the treatment of candidiasis and cryptococcosis.

Authors:  Cristina de Castro Spadari; Fernanda Walt Mendes da Silva de Bastiani; Luciana Biagini Lopes; Kelly Ishida
Journal:  Int J Nanomedicine       Date:  2019-07-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.